Skip to main content
Top
Published in: Clinical Rheumatology 7/2016

01-07-2016 | Original Article

Performance characteristics of the simplified version of ankylosing spondylitis disease activity score (SASDAS)

Authors: Dilek Solmaz, Tulay Yildirim, Okan Avci, Nazmiye Tomas, Servet Akar

Published in: Clinical Rheumatology | Issue 7/2016

Login to get access

Abstract

Various types of disease activity measures are available for axial spondyloarthritis (axSpA), and there is no gold standard for all individual patients. The ankylosing spondylitis disease activity score (ASDAS) is highly discriminatory, sensitive to change, and associated with structural progression. A simplified version of the ASDAS (SASDAS) was proposed and found to be a simple and practical tool to assess disease activity. Our aim was to test the performance characteristics of the SASDAS and compare it with validated tools. In total, 97 consecutive ankylosing spondylitis (AS) patients were included in the study. Disease activity was assessed by the ASDAS-erythrocyte sedimentation rate (ESR), ASDAS-C-reactive protein (CRP), bath ankylosing spondylitis disease activity index (BASDAI), and SASDAS. The relationship among these activity indices and the level of agreement of various activity categories were tested. There was a strong correlation between the SASDAS and other activity indices, including the BASDAI (r = 0.916, p < 0.001), ASDAS-CRP (r = 0.847, p < 0.001), and ASDAS-ESR (r = 0.942, p < 0.001). Although the agreement between the ASDAS-ESR and SASDAS was good (weighted kappa of 0.744 and total agreement of 77 %), there was moderate agreement between the ASDAS-CRP and SASDAS (weighted kappa of 0.579 and total agreement of 66 %). The disagreement was particularly striking in “moderate” and “high disease activity” states. Approximately 40 % of patients classified as moderate activity according to the ASDAS-ESR and 45 % according to the ASDAS-CRP were differentially categorized by the SASDAS. The results of the present analysis suggest that the simplified version of the ASDAS-ESR should be further validated in various settings and populations due to a questionable level of agreement between the ASDAS-CRP and SASDAS.
Literature
1.
go back to reference Godfrin-Valnet M, Prati C, Puyraveau M, Toussirot E, Letho-Gyselink H, Wendling D (2013) Evaluation of spondylarthritis activity by patients and physicians: ASDAS, BASDAI, PASS, and flares in 200 patients. Joint Bone Spine 80:393–398CrossRefPubMed Godfrin-Valnet M, Prati C, Puyraveau M, Toussirot E, Letho-Gyselink H, Wendling D (2013) Evaluation of spondylarthritis activity by patients and physicians: ASDAS, BASDAI, PASS, and flares in 200 patients. Joint Bone Spine 80:393–398CrossRefPubMed
2.
go back to reference Salaffi F, Ciapetti A, Carotti M, Gasparini S, Citera G, Gutierrez M (2014) Construct validity and responsiveness of the simplified version of Ankylosing Spondylitis Disease Activity Score (SASDAS) for the evaluation of disease activity in axial spondyloarthritis. Health Qual Life Outcomes 12:129CrossRefPubMedPubMedCentral Salaffi F, Ciapetti A, Carotti M, Gasparini S, Citera G, Gutierrez M (2014) Construct validity and responsiveness of the simplified version of Ankylosing Spondylitis Disease Activity Score (SASDAS) for the evaluation of disease activity in axial spondyloarthritis. Health Qual Life Outcomes 12:129CrossRefPubMedPubMedCentral
3.
go back to reference Machado P, Landewe R (2013) Spondyloarthritis: is it time to replace BASDAI with ASDAS? Nat Rev Rheumatol 9:388–390CrossRefPubMed Machado P, Landewe R (2013) Spondyloarthritis: is it time to replace BASDAI with ASDAS? Nat Rev Rheumatol 9:388–390CrossRefPubMed
4.
go back to reference Lukas C, Landewe R, Sieper J et al (2009) Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 68:18–24CrossRefPubMed Lukas C, Landewe R, Sieper J et al (2009) Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 68:18–24CrossRefPubMed
5.
go back to reference van der Heijde D, Lie E, Kvien TK et al (2009) ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 68:1811–1818CrossRefPubMed van der Heijde D, Lie E, Kvien TK et al (2009) ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 68:1811–1818CrossRefPubMed
6.
go back to reference Machado PM, Raychaudhuri SP (2009) Disease activity measurements and monitoring in psoriatic arthritis and axial spondyloarthritis. Best Pract Res Clin Rheumatol 28:711–728CrossRef Machado PM, Raychaudhuri SP (2009) Disease activity measurements and monitoring in psoriatic arthritis and axial spondyloarthritis. Best Pract Res Clin Rheumatol 28:711–728CrossRef
9.
go back to reference Popescu C, Trandafir M, Badica A, Morar F, Predeteanu D (2014) Ankylosing spondylitis functional and activity indices in clinical practice. J Med Life 7:78–83PubMedPubMedCentral Popescu C, Trandafir M, Badica A, Morar F, Predeteanu D (2014) Ankylosing spondylitis functional and activity indices in clinical practice. J Med Life 7:78–83PubMedPubMedCentral
10.
go back to reference Fernandez-Espartero C, de Miguel E, Loza E et al (2014) Validity of the ankylosing spondylitis disease activity score (ASDAS) in patients with early spondyloarthritis from the Esperanza programme. Ann Rheum Dis 73:1350–1355CrossRefPubMed Fernandez-Espartero C, de Miguel E, Loza E et al (2014) Validity of the ankylosing spondylitis disease activity score (ASDAS) in patients with early spondyloarthritis from the Esperanza programme. Ann Rheum Dis 73:1350–1355CrossRefPubMed
11.
go back to reference Fagerli KM, Lie E, van der Heijde DE et al (2012) Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria. Rheumatology (Oxford) 51:1479–1483CrossRef Fagerli KM, Lie E, van der Heijde DE et al (2012) Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria. Rheumatology (Oxford) 51:1479–1483CrossRef
12.
go back to reference Xu M, Lin Z, Deng X et al (2011) The Ankylosing Spondylitis Disease Activity Score is a highly discriminatory measure of disease activity and efficacy following tumour necrosis factor-alpha inhibitor therapies in ankylosing spondylitis and undifferentiated spondyloarthropathies in China. Rheumatology (Oxford) 50:1466–1472CrossRef Xu M, Lin Z, Deng X et al (2011) The Ankylosing Spondylitis Disease Activity Score is a highly discriminatory measure of disease activity and efficacy following tumour necrosis factor-alpha inhibitor therapies in ankylosing spondylitis and undifferentiated spondyloarthropathies in China. Rheumatology (Oxford) 50:1466–1472CrossRef
13.
go back to reference Aydin SZ, Can M, Atagunduz P, Direskeneli H (2010) Active disease requiring TNF-alpha-antagonist therapy can be well discriminated with different ASDAS sets: a prospective, follow-up of disease activity assessment in ankylosing spondylitis. Clin Exp Rheumatol 28:752–755PubMed Aydin SZ, Can M, Atagunduz P, Direskeneli H (2010) Active disease requiring TNF-alpha-antagonist therapy can be well discriminated with different ASDAS sets: a prospective, follow-up of disease activity assessment in ankylosing spondylitis. Clin Exp Rheumatol 28:752–755PubMed
14.
go back to reference Nas K, Yildirim K, Cevik R et al (2010) Discrimination ability of ASDAS estimating disease activity status in patients with ankylosing spondylitis. Int J Rheum Dis 13:240–245CrossRefPubMed Nas K, Yildirim K, Cevik R et al (2010) Discrimination ability of ASDAS estimating disease activity status in patients with ankylosing spondylitis. Int J Rheum Dis 13:240–245CrossRefPubMed
15.
go back to reference Eder L, Chandran V, Shen H, Cook RJ, Gladman DD (2010) Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis? Ann Rheum Dis 69:2160–2164CrossRefPubMed Eder L, Chandran V, Shen H, Cook RJ, Gladman DD (2010) Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis? Ann Rheum Dis 69:2160–2164CrossRefPubMed
16.
go back to reference Sommerfleck FA, Schneeberger EE, Buschiazzo EE, Maldonado Cocco JA, Citera G (2012) A simplified version of Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with ankylosing spondylitis. Clin Rheumatol 31:1599–1603. doi:10.1007/s10067-012-2056-7 CrossRefPubMed Sommerfleck FA, Schneeberger EE, Buschiazzo EE, Maldonado Cocco JA, Citera G (2012) A simplified version of Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with ankylosing spondylitis. Clin Rheumatol 31:1599–1603. doi:10.​1007/​s10067-012-2056-7 CrossRefPubMed
17.
go back to reference van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361–368CrossRefPubMed van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361–368CrossRefPubMed
18.
go back to reference Akad K, Solmaz D, Sari I, Onen F, Akkoc N, Akar S (2013) Performance of response scales of activity and functional measures of ankylosing spondylitis: numerical rating scale versus visual analog scale. Rheumatol Int 33:2617–2623. doi:10.1007/s00296-013-2789-x CrossRefPubMed Akad K, Solmaz D, Sari I, Onen F, Akkoc N, Akar S (2013) Performance of response scales of activity and functional measures of ankylosing spondylitis: numerical rating scale versus visual analog scale. Rheumatol Int 33:2617–2623. doi:10.​1007/​s00296-013-2789-x CrossRefPubMed
19.
go back to reference Daltroy LH, Larson MG, Roberts NW, Liang MH (1990) A modification of the Health Assessment Questionnaire for the spondyloarthropathies. J Rheumatol 17:946–950PubMed Daltroy LH, Larson MG, Roberts NW, Liang MH (1990) A modification of the Health Assessment Questionnaire for the spondyloarthropathies. J Rheumatol 17:946–950PubMed
20.
go back to reference Doward LC, Spoorenberg A, Cook SA et al (2003) Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 62:20–26CrossRefPubMedPubMedCentral Doward LC, Spoorenberg A, Cook SA et al (2003) Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 62:20–26CrossRefPubMedPubMedCentral
21.
go back to reference Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A (1994) Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 21:1694–1698PubMed Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A (1994) Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 21:1694–1698PubMed
22.
go back to reference Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174CrossRefPubMed Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174CrossRefPubMed
24.
go back to reference Machado P, Landewe R, Lie E et al (2011) Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 70:47–53CrossRefPubMed Machado P, Landewe R, Lie E et al (2011) Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 70:47–53CrossRefPubMed
Metadata
Title
Performance characteristics of the simplified version of ankylosing spondylitis disease activity score (SASDAS)
Authors
Dilek Solmaz
Tulay Yildirim
Okan Avci
Nazmiye Tomas
Servet Akar
Publication date
01-07-2016
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 7/2016
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-015-3147-z

Other articles of this Issue 7/2016

Clinical Rheumatology 7/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.